Fewer than a tenth of people that would benefit from obesity jabs like Wegovy have access to them, states the World Health Organization as it publishes its inaugural advice on the therapies.
Considering in excess of 1,000,000,000 individuals worldwide now living with obesity, it is advocating for increased and just availability to this class of drugs.
Based on forecasts, over two billion will be obese by 2030 without intervention.
"Our latest guidelines acknowledges that obesity is a lifelong illness that can be addressed with holistic and continuous treatment," stated WHO director-general Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and logistical bottlenecks are key hurdles to widespread access to the treatments that can help people shift substantial body mass, explains the body.
Weight-Loss Drug Scarcity
Despite the current most favorable outlook, the manufacturing of such drugs might only reach approximately 100 million people – less than 10% of those who need them, according to the WHO.
The guideline calls on governments and firms to expand availability, through strategies including patent sharing.
Exclusive production rights on semaglutide – the core ingredient of the drug Wegovy – is set to lapse in multiple countries in 2026.
The Way Obesity Jabs Operate
These medications imitate a biological compound to delay gastric emptying, reduce hunger and increase the sense of being full so users consume fewer calories.
People typically see weight reduction in the initial weeks of starting on the once-weekly jabs.
Evidence indicates people may regain a significant portion a year later of halting the drug, because their normal appetite come back.
Being above a healthy weight increases your risk for experiencing medical conditions, like diabetes, cardiovascular issues, stroke, and certain cancers.
Obesity affects people in countries worldwide and was responsible for millions of fatalities worldwide in 2024, according to the health agency.
